Cargando…

Summary of drug therapy to treat cognitive impairment-induced obstructive sleep apnea

Obstructive sleep apnea (OSA) is a severe sleep disorder associated with intermittent hypoxia and sleep fragmentation. Cognitive impairment is a signifi- cant and common OSA complication often described in such patients. The most commonly utilized methods in clinical OSA treatment are oral appliance...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Daqiang, Chen, Jian, Du, Xiaoxue, Xu, Linhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507626/
https://www.ncbi.nlm.nih.gov/pubmed/37731463
http://dx.doi.org/10.3389/fncel.2023.1222626
_version_ 1785107355187281920
author He, Daqiang
Chen, Jian
Du, Xiaoxue
Xu, Linhao
author_facet He, Daqiang
Chen, Jian
Du, Xiaoxue
Xu, Linhao
author_sort He, Daqiang
collection PubMed
description Obstructive sleep apnea (OSA) is a severe sleep disorder associated with intermittent hypoxia and sleep fragmentation. Cognitive impairment is a signifi- cant and common OSA complication often described in such patients. The most commonly utilized methods in clinical OSA treatment are oral appliances and continuous positive airway pressure (CPAP). However, the current therapeutic methods for improving cognitive function could not achieve the expected efficacy in same patients. Therefore, further understanding the molecular mechanism behind cognitive dysfunction in OSA disease will provide new treatment methods and targets. This review briefly summarized the clinical manifestations of cognitive impairment in OSA disease. Moreover, the pathophysiological molecular mechanism of OSA was outlined. Our study concluded that both SF and IH could induce cognitive impairment by multiple signaling pathways, such as oxidative stress activation, inflammation, and apoptosis. However, there is a lack of effective drug therapy for cognitive impairment in OSA. Finally, the therapeutic potential of some novel compounds and herbal medicine was evaluated on attenuating cognitive impairment based on certain preclinical studies.
format Online
Article
Text
id pubmed-10507626
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105076262023-09-20 Summary of drug therapy to treat cognitive impairment-induced obstructive sleep apnea He, Daqiang Chen, Jian Du, Xiaoxue Xu, Linhao Front Cell Neurosci Neuroscience Obstructive sleep apnea (OSA) is a severe sleep disorder associated with intermittent hypoxia and sleep fragmentation. Cognitive impairment is a signifi- cant and common OSA complication often described in such patients. The most commonly utilized methods in clinical OSA treatment are oral appliances and continuous positive airway pressure (CPAP). However, the current therapeutic methods for improving cognitive function could not achieve the expected efficacy in same patients. Therefore, further understanding the molecular mechanism behind cognitive dysfunction in OSA disease will provide new treatment methods and targets. This review briefly summarized the clinical manifestations of cognitive impairment in OSA disease. Moreover, the pathophysiological molecular mechanism of OSA was outlined. Our study concluded that both SF and IH could induce cognitive impairment by multiple signaling pathways, such as oxidative stress activation, inflammation, and apoptosis. However, there is a lack of effective drug therapy for cognitive impairment in OSA. Finally, the therapeutic potential of some novel compounds and herbal medicine was evaluated on attenuating cognitive impairment based on certain preclinical studies. Frontiers Media S.A. 2023-09-04 /pmc/articles/PMC10507626/ /pubmed/37731463 http://dx.doi.org/10.3389/fncel.2023.1222626 Text en Copyright © 2023 He, Chen, Du and Xu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
He, Daqiang
Chen, Jian
Du, Xiaoxue
Xu, Linhao
Summary of drug therapy to treat cognitive impairment-induced obstructive sleep apnea
title Summary of drug therapy to treat cognitive impairment-induced obstructive sleep apnea
title_full Summary of drug therapy to treat cognitive impairment-induced obstructive sleep apnea
title_fullStr Summary of drug therapy to treat cognitive impairment-induced obstructive sleep apnea
title_full_unstemmed Summary of drug therapy to treat cognitive impairment-induced obstructive sleep apnea
title_short Summary of drug therapy to treat cognitive impairment-induced obstructive sleep apnea
title_sort summary of drug therapy to treat cognitive impairment-induced obstructive sleep apnea
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507626/
https://www.ncbi.nlm.nih.gov/pubmed/37731463
http://dx.doi.org/10.3389/fncel.2023.1222626
work_keys_str_mv AT hedaqiang summaryofdrugtherapytotreatcognitiveimpairmentinducedobstructivesleepapnea
AT chenjian summaryofdrugtherapytotreatcognitiveimpairmentinducedobstructivesleepapnea
AT duxiaoxue summaryofdrugtherapytotreatcognitiveimpairmentinducedobstructivesleepapnea
AT xulinhao summaryofdrugtherapytotreatcognitiveimpairmentinducedobstructivesleepapnea